Cart
sales@molnova.com
GRGDSPK acetate
CAS No. 144027-77-0
GRGDSPK acetate( —— )
Catalog No. M36639 CAS No. 144027-77-0
GRGDSPK acetate shows inhibitory activity against integrin-fibronectin binding and can be used in research on integrins in bone formation and resorption.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 178 | Get Quote |
|
| 5MG | 256 | Get Quote |
|
| 10MG | 375 | Get Quote |
|
| 25MG | 545 | Get Quote |
|
| 50MG | 762 | Get Quote |
|
| 100MG | 1017 | Get Quote |
|
| 200MG | 1368 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameGRGDSPK acetate
-
NoteResearch use only, not for human use.
-
Brief DescriptionGRGDSPK acetate shows inhibitory activity against integrin-fibronectin binding and can be used in research on integrins in bone formation and resorption.
-
DescriptionGRGDSPK acetate shows inhibitory activity against integrin-fibronectin binding and can be used in research on integrins in bone formation and resorption.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMembrane Transporter/Ion Channel
-
TargetBeta Amyloid
-
RecptorBeta Amyloid
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number144027-77-0
-
Formula Weight775.81
-
Molecular FormulaC30H53N11O13
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(C)(O)=O.C([C@@H](NC([C@@H](NC(CNC([C@H](CCCNC(=N)N)NC(CN)=O)=O)=O)CC(O)=O)=O)CO)(=O)N1[C@H](C(N[C@@H](CCCCN)C(O)=O)=O)CCC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
MDR-1339
MDR-1339 is a blood-brain-barrier-permeable inhibitor of amyloid-β (Aβ) aggregation.
-
Aducanumab
Aducanumab (BIIB037), A selective human immunoglobulin gamma-1 (IgG1) monoclonal antibody, targets the clustered form of amyloid beta (Aβ). Aducanumab shows brain permeability and may be used to treat Alzheimer's disease (AD).
-
DSS30
DSS30 is a P25/CDK5 inhibitor.DSS30 acts by inhibiting the phosphorylation of amyloid precursor protein cleaving enzyme 1 (BACEl), which reduces the secretion of β-amyloid (Aβ).
